By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.
Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...
Amneal and mAbxience currently partner on ALYMSYS ®, a bevacizumab biosimilar, which was launched in 2022. "Amneal is building its position in the U.S. biosimilars market as this next wave of ...
Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., ...
The partnership between Amneal and mAbxience has previously resulted in the launch of ALYMSYS®, a bevacizumab biosimilar, in 2022. The proposed biosimilars could offer more affordable ...
SHANGHAI, China & JERSEY CITY, NJ, USA I March 28, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the ...
HERCESSI in the U.S., Zercepac in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab ...
Biosimilars including Filgrastim and Bevacizumab will be launched in Europe by July 2025. Aurobindo's China plant, with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback